Literature DB >> 29578033

Propranolol produces short-term facilitation of extinction in a rabbit model of post-traumatic stress disorder.

Lauren B Burhans1, Carrie A Smith-Bell2, Bernard G Schreurs2.   

Abstract

Post-traumatic stress disorder (PTSD) is a learning-based anxiety disorder with significant public health challenges due to difficulties in treating the complex, multiple symptomology. We have developed an animal model of PTSD, based on Pavlovian eyeblink conditioning in rabbits, that addresses two key features: conditioned responses (CRs) to cues associated with an aversive event and a form of conditioned hyperarousal referred to as conditioning-specific reflex modification (CRM). We have found previously that unpaired extinction is ideal for reducing both CRs and CRM simultaneously and shows sensitivity to systemic serotonergic and glutamatergic manipulations. The following study aimed to extend our work to examine the role of the noradrenergic system, dysregulation of which is strongly implicated as part of the neurobiology of PTSD and which may also play a role in the balance shift from fear reconsolidation to extinction during treatment. The goal of the following two studies was to examine whether the β-adrenergic receptor antagonist propranolol combined with either a full or brief course of unpaired extinction treatment could enhance extinction of CRs and/or CRM. Results showed a within-session facilitation of propranolol on extinction of CRs, particularly during the first extinction session, and a short-term enhancement of extinction of CRM when extinction treatment was brief. However, neither benefit translated to long-term extinction retention for the majority of subjects. Findings suggest that propranolol may provide the most therapeutic benefit in situations of high arousal early in treatment, which may be more important for future patient compliance rather than long-term treatment outcomes.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Extinction; Eyeblink conditioning; Fear conditioning; Hyperarousal; Post-traumatic stress disorder; β-adrenergic

Mesh:

Substances:

Year:  2018        PMID: 29578033      PMCID: PMC5975200          DOI: 10.1016/j.neuropharm.2018.03.029

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  79 in total

Review 1.  Neural substrates of eyeblink conditioning: acquisition and retention.

Authors:  Kimberly M Christian; Richard F Thompson
Journal:  Learn Mem       Date:  2003 Nov-Dec       Impact factor: 2.460

2.  Changes in plasma norepinephrine to combat-related stimuli among Vietnam veterans with posttraumatic stress disorder.

Authors:  E B Blanchard; L C Kolb; A Prins; S Gates; G C McCoy
Journal:  J Nerv Ment Dis       Date:  1991-06       Impact factor: 2.254

Review 3.  Virtual reality goes to war: a brief review of the future of military behavioral healthcare.

Authors:  Albert Rizzo; Thomas D Parsons; Belinda Lange; Patrick Kenny; John G Buckwalter; Barbara Rothbaum; JoAnn Difede; John Frazier; Brad Newman; Josh Williams; Greg Reger
Journal:  J Clin Psychol Med Settings       Date:  2011-06

4.  Beta-adrenoceptor blockers and the blood-brian barrier.

Authors:  G Neil-Dwyer; J Bartlett; J McAinsh; J M Cruickshank
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

5.  Grouping subjects based on conditioning criteria reveals differences in acquisition rates and in strength of conditioning-specific reflex modification.

Authors:  Carrie A Smith-Bell; Bernard G Schreurs
Journal:  Neurobiol Learn Mem       Date:  2017-10-13       Impact factor: 2.877

Review 6.  Neural circuitry and plasticity mechanisms underlying delay eyeblink conditioning.

Authors:  John H Freeman; Adam B Steinmetz
Journal:  Learn Mem       Date:  2011-10-03       Impact factor: 2.460

7.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

Review 8.  Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder.

Authors:  S M Southwick; J D Bremner; A Rasmusson; C A Morgan; A Arnsten; D S Charney
Journal:  Biol Psychiatry       Date:  1999-11-01       Impact factor: 13.382

Review 9.  Revisiting propranolol and PTSD: Memory erasure or extinction enhancement?

Authors:  Thomas F Giustino; Paul J Fitzgerald; Stephen Maren
Journal:  Neurobiol Learn Mem       Date:  2016-01-22       Impact factor: 2.877

10.  Systemic propranolol acts centrally to reduce conditioned fear in rats without impairing extinction.

Authors:  Jose Rodriguez-Romaguera; Francisco Sotres-Bayon; Devin Mueller; Gregory J Quirk
Journal:  Biol Psychiatry       Date:  2009-02-26       Impact factor: 13.382

View more
  7 in total

1.  Myocardial hypersensitivity to ischemic injury is not reversed by clonidine or propranolol in a predator-based rat model of posttraumatic stress disorder.

Authors:  Boyd R Rorabaugh; Albert D Bui; Sarah L Seeley; Eric D Eisenmann; Robert M Rose; Brandon L Johnson; Madelaine R Huntley; Megan E Heikkila; Phillip R Zoladz
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2018-09-05       Impact factor: 5.067

2.  Inactivation of the interpositus nucleus blocks the acquisition of conditioned responses and timing changes in conditioning-specific reflex modification of the rabbit eyeblink response.

Authors:  Lauren B Burhans; Bernard G Schreurs
Journal:  Neurobiol Learn Mem       Date:  2018-07-24       Impact factor: 2.877

3.  Inactivation of the interpositus nucleus during unpaired extinction does not prevent extinction of conditioned eyeblink responses or conditioning-specific reflex modification.

Authors:  Lauren B Burhans; Bernard G Schreurs
Journal:  Behav Neurosci       Date:  2019-03-14       Impact factor: 1.912

Review 4.  Brain and Cognition for Addiction Medicine: From Prevention to Recovery Neural Substrates for Treatment of Psychostimulant-Induced Cognitive Deficits.

Authors:  Manoranjan S D'Souza
Journal:  Front Psychiatry       Date:  2019-07-24       Impact factor: 4.157

Review 5.  Pharmacotherapy of anxiety disorders in the 21st century: A call for novel approaches.

Authors:  Eric Bui; Franklin King; Andrew Melaragno
Journal:  Gen Psychiatr       Date:  2019-12-11

Review 6.  Propranolol versus Other Selected Drugs in the Treatment of Various Types of Anxiety or Stress, with Particular Reference to Stage Fright and Post-Traumatic Stress Disorder.

Authors:  Łukasz Szeleszczuk; Dawid Frączkowski
Journal:  Int J Mol Sci       Date:  2022-09-03       Impact factor: 6.208

7.  Acute stress leaves fear generalization in healthy individuals intact.

Authors:  Franziska Magdalena Kausche; Gundula Zerbes; Lea Kampermann; Jana Christina Müller; Klaus Wiedemann; Christian Büchel; Lars Schwabe
Journal:  Cogn Affect Behav Neurosci       Date:  2021-02-24       Impact factor: 3.282

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.